Ross Cagan, Ph.D.
Icahn School of Medicine at Mount Sinai, New York City
Dr. Cagan is currently Professor in the Department of Developmental and Regenerative Biology, and Director of the Center for Personalized Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai, New York City, as well as Senior Editor of the journal Disease Models and Mechanisms and co-founder of the biotechnology company Medros Inc. Dr. Cagan has pioneered the use of Drosophila to identify therapeutic leads for cancer including helping identify the first FDA-approved chemotherapeutic for Medullary Thyroid Carcinoma. His laboratory has developed a novel drug discovery platform that combines genetics with medicinal and computational chemistry. Dr. Cagan leads the CPCT team that develops and treats thyroid and colorectal cancer patients through a personalized fly-to-bedside, open label clinical trial.
At "Future Medicine" he will talk about "Fly to Bedside".